A Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 16 Mar 2018
At a glance
- Drugs Risankizumab (Primary) ; Methotrexate
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 12 Mar 2018 Planned End Date changed from 3 Sep 2021 to 31 Aug 2021.
- 12 Mar 2018 Planned initiation date changed from 22 May 2018 to 30 Jun 2018.
- 30 Oct 2017 Planned End Date changed from 16 Sep 2021 to 3 Sep 2021.